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Since 1990, Romania turned itself slowly but surely, from a large drugs producer, which 
has used to supplydrugs to the whole former Council for Mutual Economic Assistance 
Member States, and with a net positive trade balance in medicine sector, into a large 
drugs importer, trying hardly to attract investors which could produce medicines not only 
for the Romanian domestic market, but also for all other Eastern European markets, 
Ukraine, Russia and Turkey. 
This  paper  focuses  on  the  empirical  analisys  of  the  medicines  production  sector  in 
Romania after 1990, aiming to emphasises the factors which have mostly affected this 
industry,  in  correlation  with  different  interests  and  reasons  which  determined  the 
increasing imports of drugs during the last years, by underlying at the same time, the role 
of  the  new  public  authority  in  charge  of  supervising  the  distribution  and  import  of 
medicines in Romania, The National Medicines Administration (NMA). 
The paper relevance relies in the fact that Romania registered during the last years drug 
imports of an average of 1.7 billion euros, while the drug exports were only around 0,1 
billions  euros,  according  to  the  computations  made  on  the  data  provided  by  the 
Romanian Institute of National Statistics (INS). The most imported products are patent 
drugs, which are more expensive than those produced by the domestic manufactured. At 
the same time, Romania registered an increase of the pharmaceutical market of around 
20% only since its EU integration, this market proven to be largely driven by expensive 
products.  
Our research conducted to the conclusion that the Romanian resort authorities have to 
immediately adopt measures meant to limit consumption of expensive drugs, on the one 
side, and to reinforce the domestic manufacturers on the other side, even by attracting 
major  investors  in  this  sector.  We  have  also  identified  that  there  is  a  large 
competitiveness for Romanian medicine products on the international market, due to its 
production costs (Romania still is a low cost economy in this sector), as well as due to its 
tradition. 
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Pharmacies  and  pharmacists  were  among  the  first  health  care  facilities  and  health 
professionals in Romania that were privatized or allowed to operate private businesses, 
respectively. Since 1998, the public authority in charge of supervising the distribution and 
import of drugs in Romania is The National Medicines Administration (NMA), which, 
according to its web site, authorizes both production and import of medicines in Romania, 
depending on their source: for import activities (i.e., import in Romania of medicines 
from extra-EEA countries), an import authorization is required; for distribution activities 
(i.e.,  distribution in  Romania  of  drugs  from  EEA  countries), a  wholesale  distribution 
authorization  is  issued.  The  orders  issued  by  NMA  in  December  2008  regulate  the 
procedure and conditions for the issuance of the import authorization or the wholesale 
authorization. The new regulatory framework establishes that a wholesale authorization is 
necessary even for merely invoicing the medicines. 
Although Romanian drug production has drastically decreased after 1990, Romania has 
become during the last years of interest for the multinational companies producing drugs. 
For  this  reason,  the  Romanian  drugs  exports  rose  lately,  but  there  still  is  a  big  gap 
between the imports and the exports of medicines: Romania registered during the last 
years drug imports of an average of 1.7 billion Euros, while the drug exports were only 
around 0.1 billion Euros, according to the computations made on the data provided by the 
Romanian Institute of National Statistics (INS) (see Table 1). As it concerns the imports, 
the main supplier is Hungary, followed very close by Germany and France.  
 











 Year  2006  2007  2008  2006  2007  2008 
   Total  25850  29549  33725  40746  51322  57240 
5  Chemicals and related 
products, n.e.s.  1533  1693  2050  4581  5238  6185 
54  Medical  and 
pharmaceutical products  108  87  163  1519  1495  1849 
Data source: INS 
Note: SITC, REV. 4 - Standard International Trade Classification.   
 
If before 1990, there were only 4 big national drugs producers in Romania – Sicomed, 
Antibiotice, Terapia and Biofarm -, after 1990 those producers have been bought and 
modernised by foreign investors, which have also diversified their products’ portofolio. 
As a result, some former national brands like Rinofug, Boicil or Ciocolax disappeared, 
while  some  others,  like  Faringosept,  still  have  success,  being  exported  to  the  old 
traditional markets, like Russia and Ukraine. For example, only in 2010, the exports of 
Faringosept produced by Terapia-Ranbaxy, part of the Daiichi-Sankyo group, to these 
markets, valued 13 mil. Euros out of the total of 15 mill. Euros exported. 
The foreign investors own these days the biggest share of the Romanian generic drugs 
production, being strategic partners of the Romanian public health system, confronted 
with big financial issues, which lead in 2010, to a change in the national legislation 126 
permitting the creation of a partnership between the public authorities and the business 
environment.  This  partnership  is  based  on  the  compensation  mechanism  which  is  in 
favour of the generic drugs, meant to save the incomes to the public budget. From this 
perspective,  by  the  end  of  2011,  the  investments  of  the  generic  drugs  producers  in 
Romania are expected to grow more over 2 bn. Euros as it was registered at the end of 
2010,  but  these  investments  must  be  oriented  to  human  resources,  licences,  and  the 
development of the home production facilities, in order to produce the expected positive 
results.  
Pharmaceutical manufacturing, distribution systems and quality are controlled by 
legislation, there being no formal pharmaceutical policy in Romania, but only 
tools for regulating the pharmaceutical market and its links with the health care 
system (NMA web site). 
Production is inspected by the NMA, while distribution warehouses and pharmacies are 
inspected by the Ministry of Health and the counties’ public health authorities (CPHAs). 
Producers cannot have their own wholesale distribution or pharmacies. The government 
has only two facilities where the state (Ministry of Health) still holds a share: Antibiotice 
Iasi  (producer  of  generic  drugs,  mainly  antibiotics)  and  Unifarm  (distributor).  These 
facilities  do  not  benefit  from  any  protectionist  measures  and  compete  with  all  other 
existing private companies in Romania. The latest ones have registered good results so far 
in  Romania:  8  companies  -  Terapia-Ranbaxy,  Antibiotice,  Biofarm,  Gedeon-Richter, 
Labormed, Actavis, Sandoz and Zentiva – had 0.4 bn. Euros turnover only in 2009, while 
having a total of over 7.500 employees.  
Hospitals are supplied with drugs by wholesalers, and purchasing is regulated by the 
public  acquisition  law.  According  to  the  NMA,  commercial  relations  between 
wholesalers  and  retailers  (pharmacies)  are  not  regulated  except  for  ensuring  that  the 
wholesaler mark-up does not exceed 9%. 
The Romanian Ministry of Health is responsible for the registration and licensing of 
pharmacies. The total number of pharmacies in 2010 licensed and registered was more 
than  6000.  Out  of  these,  approximately  75%  had  contractual  relations  with  a  health 
insurance  fund,  but  only  contracted  pharmacies  are  permitted  to  sell  drugs  that  are 
included in the public compensation scheme. The criteria used to select these pharmacies 
are  as  follows:  professional  qualifications  of  the  employees  and  the  accessibility  to 
potential beneficiaries (patients). In urban areas, there were more than 75% out of total 
pharmacies registered while in rural areas are the rest. 
Drug  registration  is  the  responsibility  of  the  NMA,  where  data  exclusivity  operates 
according  to  the  European  Union  requirements.  Bolar  provision  operates  too,  but 
compulsory licensing was never used. The regulations are compliant with the Agreement 
on  Trade-Related  Aspects  of  Intellectual  Property  Rights  (TRIPS).  In  present, 
approximately  7000  drugs  are  registered  in  Romania,  and  there  are  some  100  new 
applications for registration every month. 
The continuing rise in cost of medicines during the transition period has caused increased 
concern to the Ministry of Health and the Government in general, but however, measures 
for  cost-containment  and  drug  regulation  have  been  introduced  on  an  ad  hoc  basis. 
According to the drug law, the Ministry of Health establishes the maximum retail prices 
of  both locally  produced  or  imported  pharmaceutical  products,  with  the  exception  of 
over-the-counter (OTC) drugs. Prices for these drugs are not regulated by Ministry of 127 
Health, these being freely sold on the market. However producers or importers of OTC 
drugs need to notify the Ministry of Health about prices of their products on a quarterly 
basis.  
The NMA gives approval for alternative/complementary medicines to be marketed but 
the Ministry of Health does not regulate their prices. After a new drug is registered at the 
NMA, the Ministry of Health gives it a price before the product is allowed to be marketed 
in  Romania.  For  drugs  that  are  already  registered,  producers  also  need  to  apply  to 
Ministry of Health for a price if a price increase is requested. When requesting a price 
increase, producers are usually simply changing the packaging size or size of tablets. 
Permission for price increase is seldom granted. 
Producers  and  importers  have  to  present  their  manufacturer  price  to  the  Ministry  of 
Health. Importers are asked for the price from country of origin and the price for which 
they have bought the product (cost, insurance and freight price), while local producers are 
asked for the level of production costs, profit and wholesaler price. Based on information 
provided by the importer or producer, prices are usually compared with prices of the same 
product already on the market in the following countries: the Czech Republic, Bulgaria, 
Hungary and, if necessary, Austria, Belgium, Italy, Poland and Slovakia. The lowest price 
is considered. No other comparison tools are used. Both importer and local producers are 
allowed to take a gross profit margin of 7.5%. Only the importer can add a further mark-
up of 8.5% for services connected to the import. The total mark-up for imported drugs 
was 30% until 2003; since then it has gradually decreased. 
Price adjustments can take place on a yearly basis by applying a formula that takes into 
account the currency exchange rates between the adjustment dates. Prices are published in 
a drug catalogue that is updated quarterly and it is available on Internet, at the web 
address www.msf-dgf.ro. 
The  mark-up  of  the  wholesaler  and  the  pharmacist  is  dependent  on  the  price  of  the 
package (usually one-month’s supply of medication). Some importers give discounts to 
wholesalers;  wholesalers  give  discounts  to  pharmacists,  and  the  total  mark-up  of  the 
wholesaler and pharmacist varies from 12% for prices over €2.14 and 24% for prices 
below €0.5. 
In  Romanian,  there is  an increasing  domestic  demand  of  drugs,  which  will  keep  the 
foreign  investors  in  the  country.  According  to  the  Romania  Pharmaceuticals  and 
Healthcare Report, which provides data and forecasts about the Romanian market, the 
total pharmaceutical sales in Romania, in 2010, were around RON10.78bn (2.5 bn Euros), 
making Romania the seventh-largest market in Emerging Europe (see Figure 1). 
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Figure 1. The Evolution of the Romanian Pharmaceutical Market 
Source:  http://rbd.doingbusiness.ro/ro/1/articole-recente/1/94/romanian-pharmaceutical-market, 
accessed in January 2011 
 
Labormed was the first greenfield investor in the Romanian drugs industry, and initially 
invested  19  mill.  Euros  in  2007.  Thereafter,  Labormed  was  bought  by  the  Advent 
International  Investment  Fund.  At  that  time,  the  surface  of  the  factory  was  of  about 
10.000 qm., had 230 employees, a production capacity of 60000 commercial units per 
year, and a portofolio of 216 products, out of which 162 for the internal market. Its most 
successful export product is Prostacare plus, mainly sold on the Polish market.  
A big domestic producer is Sanofi-Aventis / Zentiva, which has a production capacity of 
over 100 mill. Commercial units per year, and annual investments of 10 mill. Euros, 
which will continue in the next years. 
Actavis is another producer of drugs in Romania, which employed over 150 specialists 
and produce over 2 mill. commercial units of oncological drugs per year, out of which 
40%  are  for  domestic  market.  The  top  exported  Actavis  products  are  Gemcitabina, 
Irinotecan  and  Fludarabina,  produced  mainly  by  the  Sindan  Pharma  factory  of  the 
Actavis. This top international producer and dealer of generic drugs have also acquired 
other former Romanian drugs factories, such as Antibiotice Iasi and Terapia Cluj-Napoca, 
as well as new factories developed after 1990, like Sandoz and Gedeon-Richter in Targu-
Mures, and Europharm-GSK in Brasov. 
GSK produces medicaments both for internal and external markets, currently exporting in 
more than 50 countries across the globe. In 2010, its exports represented 43% of the total 
production, equivalent of 18.5 mill. commercial units. Since 2008, its exports rose with 
186% in 2009 compared to 2008, and in 2010, with 330% compared to 2009. These 
results are due to those over 100 mill. Euros invested by the company in Romania during 
the last 12 years. 
Other drugs producers are located in Targu-Mures, where Sandoz and Gedeon Richter 
have established their production units. In 1998, Gedeon Richter acquired Armedica S.A., 
which was renamed Gedeon Richter Romania S.A. in 2003, and has in present over 550 129 
employees,  out  of  which  more  than  a  half  have  University  degrees.  Its  top  exported 
products are tamsulosina, simvastatina and haloperidolul. Sandoz also exports a big share 
of its production in Romania.  
With all lately foreign investments in Romania, the country is at the bottom of the top of 
the country with biggest research investments in drugs production and development, with 
only 5 Euros per capita in average, during the last 5 years, similar to Portugal and Greece, 
and opposite to Denmark (190 Euros per capita), Belgium (170 Euros per capita), and 
Sweden (80 Euros per capita). From this point of view, Romania certainly does not have 
the dilemma of the most developed countries, which have to deal with issues like opting 




Because of the fact that Romania has a European minimum price for the drugs to sell, 
there is an even bigger market for the re-exports and parallel exports, which means that 
the drug is imported in Romania to the minimum price in the EU, and then is re-exported 
to other markets, to be sold at a higher price. Unfortunately, also the generic drugs are 
exported to foreign markets, only because the Romanian government insisted that these 
drugs to be sold at the lowest European price, even for the innovator drugs. The situation 
resulted in a paradox of the Romanian drugs market: the domestic producers prefer to 
export,  due  to  the  export  prices  and  to  the  fact  that  the  government  reimburse  the 
domestic producers with a nine months delay, while the domestic population, due to the 
lack of domestic drugs, buy imports drugs, which are very expensive. By consequence, as 
long as the domestic producers receive the money from the Romanian budget with a 9 
months delay, the export will represent their only way to enhance the cash-flow. 
Romania  has  some  strength  which  could  encourage  the  foreign  investors  to  further 
produce drugs in the country, such as: tradition in producing drugs, specialised labour 
force, and good potential to raise the internal consumption. It must consider also the 
average  domestic  consumption  which  is  about  100  Euros  per  year,  while  the  region 
average is around 250 Euros per year, suggesting that in Romania there still is much 
potential for this market, both in volume and value. Furthermore, Romania is between 
those 17 emerging markets which, according to the IMS Health forecasts, will raise their 
turnover with more than 90 bn. Euros till 2013, contributing this way to an increase of the 
global pharmaceutical market of around 48% in 2013. 
Besides, it has to be further considered the fact that in order to attract foreign investments, 
the law and the economic system are very important, both representing the weakness of 
Romania, because of their instability. 
 
Acknowledgements 
This paper results from empirical research pursued by the leading author in the project: 
“Study concerning the identification and the improvement of the Romanian companies 
developing external trade activities’ competitive advantages, for maximizing the positive 
effects  of  the  EU  accession”  (SVACEX),  financed  by  the  Romanian  Authorities 







1.  Giurgiu,  Adriana.  Comer￿ul  intraeuropean.  O  nou￿  perspectiv￿  asupra  comer￿ului 
exterior al României (Intra-European Trade. A New Perspective onto the External Trade 
of Romania), Bucure￿ti: Editura Economic￿, 2008. 
 
Journal Articles / On-line Journals 
2.  Doing  Business,  visited  in  January,  2011.  http://rbd.doingbusiness.ro/ro/1/articole-
recente/1/94/romanian-pharmaceutical-market 
3. Giurgiu, Adriana. "An Overview of the General Evolution of the Romanian Foreign 
Trade after 1989, while trying to join the EU (I, II)," University of Oradea - Annals of 
Faculty  of  Economics,  vol.  1(1)/2010:53-58,  visited  on  March,  2011. 
http://ideas.repec.org/a/ora/journl/v1y2010i1p53-58.html  and 
http://ideas.repec.org/a/ora/journl/v1y2010i2p100-106.html.  
4.  Giurgiu,  Adriana.  „The  leading  economic  sectors  building  comparative  and 
competitive  advantages  in  Romania's  foreign  trade”,  Economie  teoretic￿  ￿i 




5.  Eudra  GMP.  Accessed  on  March-April  2011. 
http://eudragmp.emea.europa.eu/inspections/selectLanguage.do.  
6.  INS  (Romanian  Institute  of  National  Statistics).  Accessed  on  January-April  2011. 
www.insse.ro.  
7.  Research  and  Markets.  Accessed  on  January-April  2011. 
http://www.researchandmarkets.com/research/8e2ae7/romania_pharmaceut.  
8. The National Medicines Administration (NMA). Accessed on February-April 2011. 
http://www.anm.ro/. 
9.  World  Health  Organiyation  (WHO).  Accessed  on  March-April  2011. 
http://www.euro.who.int/en/what-we-do/health-topics/Health-systems/medicines/country-
work2/a-selection-of-country-profiles/romania-2008. 
   